This site is intended for healthcare professionals

National Institute for Health and Care Excellence (NICE) recommends relugolix combination therapy to treat uterine fibroids.- Gedeon Richter.

Read time: 1 mins
Published:14th May 2022

In a final draft guidance the National Institute for Health and Care Excellence (NICE) has recommended relugolix-estradiol-norethisterone acetate (Ryeqo; Gedeon Ritcher UK) for the treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age.


Following the decision by NICE, around 4500 women with uterine fibroids will be eligible to receive the drug. Sold under the brand name Ryeqo in the EU (Myfembree in the US), the drug will be accessible to patients 3 months after the final guidance is issued.

Condition: Uterine Fibroids
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights